Patents by Inventor Kittikhun WANGKANONT

Kittikhun WANGKANONT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Probiotic function of human intelectin
    Patent number: 10413588
    Abstract: The present disclosure provides for methods providing a pre/probiotic agent to a subject. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria, thereby promoting and protecting the microbiome.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: September 17, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Laura L. Kiessling, Darryl A. Wesener, Federico Rey, Kittikhun Wangkanont
  • Microbial glycans as a target of human intelectin
    Patent number: 10082506
    Abstract: The present disclosure provides for methods of diagnosing and treating bacterial infections. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria including Streptococcus pneumonia, Proteus mirabilis, Proteus vulgaris, Klebsiella pneumonia and Yersinia pestis. This interaction can be targeted to identify, purify and therapeutically target such organisms.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: September 25, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Laura L. Kiessling, Darryl A. Wesener, Kittikhun Wangkanont
  • PROBIOTIC FUNCTION OF HUMAN INTELECTIN
    Publication number: 20170136088
    Abstract: The present disclosure provides for methods providing a pre/probiotic agent to a subject. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria, thereby promoting and protecting the microbiome.
    Type: Application
    Filed: November 3, 2016
    Publication date: May 18, 2017
    Inventors: Laura L. KIESSLING, Darryl A. WESENER, Federico REY, Kittikhun WANGKANONT
  • MICROBIAL GLYCANS AS A TARGET OF HUMAN INTELECTIN
    Publication number: 20160131649
    Abstract: The present disclosure provides for methods of diagnosing and treating bacterial infections. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria including Streptococcus pneumonia, Proteus mirabilis, Proteus vulgaris, Klebsiella pneumonia and Yersinia pestis. This interaction can be targeted to identify, purify and therapeutically target such organisms.
    Type: Application
    Filed: November 5, 2015
    Publication date: May 12, 2016
    Inventors: Laura L. KIESSLING, Darryl A. WESENER, Kittikhun WANGKANONT